Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study
Osamu Maeda, Ayumu Matsuoka, Yuichi Ando, Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya 466-8560, Japan
Ryoji Miyahara, Kohei Funasaka, Hidemi Goto, Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
Yoshiki Hirooka, Department of Endoscopy, Nagoya University Hospital, Nagoya 466-8560, Japan
Masahide Fukaya, Masato Nagino, Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 466-8550 Nagoya, Japan
Yasuhiro Kodera, Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, 466-8550 Nagoya, Japan
Author contributions: Maeda O and Ando Y designed the research, performed the protocol treatment and wrote the manuscript; Matsuoka A, Miyahra R, Funasaka K and Fukaya M contributed to performing the protocol treatment; Hirooka Y, Nagino M, Kodera Y and Goto H were involved in patient recruitment and data analysis.
Institutional review board statement: This study was approved by the review boards of Nagoya University Hospital.
Clinical trial registration statement: This study was registered at http://www.umin.ac.jp/ctr/index.htm, registration identification number is UMIN000006009.
Informed consent statement: All patients provided written informed consent.
Conflict-of-interest statement: Kodera Y has received research funding from Chugai Pharmaceutical Co., Ltd., Sanofi, Yakult Honsha Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., and Bristol-Myers Squib. Goto H has received research funding from Bristol-Myers Squibb, and Takeda Pharmaceutical Co., Ltd. Ando Y has received research funding from Sanofi, Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Honsya Co., Ltd., and Mochida Pharmaceutical Co., Ltd.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Osamu Maeda, MD, PhD, Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Aichi, Japan. firstname.lastname@example.org
Telephone: +81-52-7441903 Fax: +81-52-7441903
Received: October 20, 2016
Peer-review started: October 24, 2016
First decision: October 28, 2016
Revised: December 19, 2016
Accepted: January 17, 2017
Article in press: January 17, 2017
Published online: February 14, 2017